- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05592379
Consciousness, Psilocybin, and Well-Being (CoPE Pilot)
Consciousness and Psilocybin Effects on Well-Being (The CoPE Study): Pilot Phase
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study intervention will be psilocybin administered by the intravenous (IV) route to sleeping and awake participants. The study will test up to two different IV administration protocols in sleeping participants. The first protocol to be tested will consist of 2 mg of psilocybin administered via IV infusion over a 2-minute period. Should this method allow participants to remain asleep for at least 1 hour post-dosing, no further dosing strategies will be evaluated. If the 2-minute IV infusion delivery method disrupts sleep, a second dosing strategy will be examined consisting of 2 mg of IV psilocybin administered over 10 minutes. Whichever dosing strategy causes the least sleep disruption will be selected for administration to awake participants.
As part of the study design, some participants may also receive normal IV saline instead of IV psilocybin during the dosing session. For any given participant, the protocol for delivering the normal saline will be identical to the psilocybin protocol they receive (e.g., either IV saline (10 mL) over 2 minutes or IV saline (10 mL) over 10 minute IV infusion).
Participants will include medically and psychiatrically healthy biological males and females of any identified gender and racial/ethnic group aged 18 to 45 years.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53715
- University of Wisconsin Hospital and Clinics
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Medically healthy
- English-speaking
- Live within 150 miles of Madison, WI for duration of study
Exclusion Criteria:
- Current use of medications that may interact with psilocybin
- Current sleep disorder, including (but not limited to) insomnia, sleep apnea, restless legs syndrome, and/or narcolepsy
- Females with positive urine pregnancy at any time point during screening or study participation
- Current cardiac valve disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 2-minute IV Psilocybin/Placebo Infusion - Asleep
Participants will receive 2mg of IV psilocybin over 2 minutes while asleep during an overnight visit and 10 mL of placebo (saline) over 2 minutes while asleep during another overnight visit.
The order of administration will be determined by the study protocol.
|
The IV formulation of psilocybin will be prepared using bulk psilocybin that will satisfy Good Manufacturing Practice (GMP) criteria. The IV psilocybin solution will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center (PRC). The IV placebo (saline) will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center.
Other Names:
|
Experimental: 2-minute IV Psilocybin/Placebo Infusion - Awake
Participants will receive either 2mg of IV psilocybin or 10 mL of IV saline (placebo) over 2 minutes during an overnight visit while awake.
|
The IV formulation of psilocybin will be prepared using bulk psilocybin that will satisfy Good Manufacturing Practice (GMP) criteria. The IV psilocybin solution will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center (PRC). The IV placebo (saline) will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center.
Other Names:
|
Experimental: 10-minute IV Psilocybin/Placebo Infusion - Asleep
Participants will receive 2mg of IV psilocybin over 10 minutes while asleep during an overnight visit and 10 mL of placebo (saline) over 10 minutes while asleep during another overnight visit.
The order of administration will be determined by the study protocol.
|
The IV formulation of psilocybin will be prepared using bulk psilocybin that will satisfy Good Manufacturing Practice (GMP) criteria. The IV psilocybin solution will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center (PRC). The IV placebo (saline) will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center.
Other Names:
|
Experimental: 10-minute IV Psilocybin/Placebo Infusion - Awake
Participants will receive either 2mg of IV psilocybin or 10 mL of IV saline (placebo) over 10 minutes during an overnight visit while awake.
|
The IV formulation of psilocybin will be prepared using bulk psilocybin that will satisfy Good Manufacturing Practice (GMP) criteria. The IV psilocybin solution will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center (PRC). The IV placebo (saline) will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number and nature of adverse events associated with the administration of a single dose of IV psilocybin while asleep or awake
Time Frame: Up to 9 days
|
Adverse event grading will be done using Common Terminology Criteria for Adverse Event (CTCAE)Adverse events will be graded from Grade 1-5 depending on severity.
Grade 1 - mild, grade 2 - moderate, grade 3 - severe, grade 4 - Life threatening, grade 5 - Fatal.
Adverse events will be collected on an Adverse Event Log throughout the study.
|
Up to 9 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of subjects administered IV psilocybin while asleep who remain asleep for at least 1 hour post dosing
Time Frame: 1 day
|
1 day
|
|
Post-dosing scores on the Psychological Insight Scale (PIS) following administration of IV psilocybin while asleep or awake
Time Frame: 1 day
|
The PIS is a 6-item self-report scale that queries the acquisition of insight following a psychedelic therapy.
The items are answered with visual analogue scales anchored by "no more than usually" on the left and "much more than usually" on the far right.
A seventh item separately assesses self-reported behavioral change resulting from the psychedelic experience.
The total possible range of scores for the PIS is 0-100 with higher scores indicating a greater psychological insight.
|
1 day
|
Warwick-Edinburgh Mental Well-Being Scale (WEMWBS) score 7 days post administration of IV psilocybin while asleep or awake
Time Frame: Up to 19 days
|
The WEMWBS is a 14-item self-report scale that was designed to measure the psychological well-being of a population.
The questions use a five-point Likert scale.
The items are all worded positively and cover both feeling and functioning aspects of mental wellbeing.
Items on the questionnaire are rated on a 5-point scale, where 1= "None of the time", 2= "rarely", 3= "some of the time", 4= "often", 5= "all the time".
A total scale score is calculated by summing the 14 individual item scores.
The total possible range of scores for the WEMWBS is 14-70 with higher scores indicating a greater well-being.
|
Up to 19 days
|
World Health Organization Well-Being Index
Time Frame: Up to 19 days
|
World Health Organization Well-Being Index (WHO-5) is a 5-item survey with a total possible range of scores 0-25 where higher scores indicate increased well-being.
|
Up to 19 days
|
Post-dosing scores on the 30-item Mystical Experiences Questionnaire (MEQ30) following administration of IV psilocybin while asleep or awake
Time Frame: 1 day
|
The MEQ30 is a 30-item self-report measure developed to assess the effects of classic psychedelics in laboratory studies.
It covers the major dimensions of the classic mystical experience: unity, transcendence, noetic quality, sacredness, positive mood, and ineffability/paradoxicality.
The MEQ has 4 sub scales: 1) transcendence, 2) positive mood, 3) ineffability, and 4) mystical.
The total possible range for each sub scale and total score is 0-100% with higher percentages indicating a larger mystical experience.
Typically, a complete mystical experience is defined as scoring 60% or more on all four MEQ30 subscales.
|
1 day
|
Post-dosing scores on the Emotional Breakthrough Inventory (EBI) following administration of IV psilocybin while asleep or awake
Time Frame: 1 day
|
The EBI is a 6-item self-report scale that assesses the presence and severity of emotionally challenging/distressing experiences that occur during a psychedelic experience.
The scale utilizes visual analog responses captured on a line anchored by "not at all" on one end and "very much so" on the other.
Experiences queried include 1) facing emotionally difficult feelings that are usually pushed aside; 2) experiencing a resolution of a personal conflict/trauma; 3) being able to explore challenging emotions and memories; 4) having an emotional breakthrough; 5) getting a sense of closure on an emotional problem, and 6) achieving an emotional release followed by a sense of relief.
The total possible range of scores for the EBI is 0-100 with higher scores indicating a greater emotional breakthrough.
|
1 day
|
Post-dosing scores on the Ego Dissolution Inventory (EDI) following administration of IV psilocybin while asleep or awake
Time Frame: 1 day
|
The EDI is an 8-item self-report scale designed to measure ego-dissolution.
Each item is scored on a visual analogue scale from 0 to 100 with the following statements at the lower and upper end, respectively: "No, not more than usually" and "Yes, I experienced this completely/entirely."
The total possible range of scores for the EDI is 0-100 with higher scores indicating a greater ego dissolution.
|
1 day
|
Post-dosing scores on the Awe Experiences Scale (AWE) following administration of IV psilocybin while asleep or awake
Time Frame: 1 day
|
The AWE is a 30-item self-report scale that measures the state of awe.
Each items is rated on a scale of 1 to 7, with 1 representing "Strongly Disagree" and 7 representing "Strongly Agree".
The total possible range of scores for the AWE is 1-7 with higher scores indicating a greater awe.
|
1 day
|
Post-dosing scores on the Altered States of Consciousness Questionnaire (ASC) following administration of IV psilocybin while asleep or awake
Time Frame: 1 day
|
The ASC is a 94-item self-report scale that assesses alterations from your normal waking consciousness.
Each item is scored on a visual analogue scale from 0 to 100 with the following statements at the lower and upper end, respectively: "No, not more than usually" and "Yes, much more than usually."
The total possible range of scores for the ASC is 0-100 with higher scores indicating a greater state of altered consciousness.
|
1 day
|
Post-dosing scores on the Challenging Experiences Questionnaire (CEQ) following administration of IV psilocybin while asleep or awake
Time Frame: 1 day
|
The CEQ is a 26-item questionnaire that consists of seven factors of challenging experience with psilocybin mushrooms: fear, grief, feeling of losing your sanity (insanity), feel as though you are dying (death), feelings of isolation, physiological distress, and paranoia.
The CEQ uses a 6-point response scale [0: None/not at all, 1: So slight cannot decide, 2: Slight, 3: Moderate, 4: Strong; 5: Extreme (more than ever before in my life)] to indicate the degree to which a participant experiences each of a series of subjective effects during their psilocybin session.
Total CEQ score is expressed as the percentage of the total possible ratings on the scale.
The total possible range of scores for the CEQ is 0-5 with higher scores indicating a greater challenging experience.
|
1 day
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Charles Raison, MD, University of Wisconsin, Madison
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-0746
- A532017 (Other Identifier: UW Madison)
- 233897 (Other Identifier: OnCore ID)
- Protocol Version 2/2/2024 (Other Identifier: UW Madison)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Psilocybin and Saline
-
Yale UniversityHeffter Research Institute; Ceruvia Lifesciences; CH TAC LLCCompleted
-
University of Wisconsin, MadisonTRYP TherapeuticsWithdrawn
-
Yale UniversityCeruvia LifesciencesCompleted
-
King's College LondonUniversity of CambridgeRecruitingAutism Spectrum DisorderUnited Kingdom
-
Yale UniversityHeffter Research InstituteActive, not recruitingMajor Depressive DisorderUnited States
-
Section for Affective Disorders; Northern Stockholm...Karolinska Institutet; Vastra Gotaland Region; Region Örebro County; Uppsala University...Recruiting
-
University Health Network, TorontoCentre for Addiction and Mental HealthRecruitingDepression | Mood Disorders | Major Depressive Disorder | Treatment-Resistant DepressionCanada
-
Yale UniversityTerminated
-
Multidisciplinary Association for Psychedelic StudiesWithdrawnAnxiety | Stage IV MelanomaUnited States
-
University of Colorado, DenverNot yet recruitingAnhedonia | Major Depressive Disorder | Treatment Resistant DepressionUnited States